Ostase® BAP EIA
Cat No.: AC-20F1

CE Marked
FDA Cleared

Clinical Area: Bone Metabolism
Type: Manual
Format: EIA
Number of Tests: 96 (40 samples in duplicate)
Sample Type: Serum
Sample Volume: 50 μL
Assay Range: 7-90 μg/L


The Ostase® BAP EIA Immunoenzymetric Assay is an in vitro device indicated for the quantitative measurement of bone-specific alkaline phosphatase (BAP), an indicator of osteoblastic activity, in human serum. BAP, also known as bone ALP, is intended to be used as an aid in the management of rickets in children, postmenopausal osteoporosis and deformable osteoarthritis. Meanwhile, it has been clinically proved that the treatment of bone metabolic diseases can be effectively monitored and evaluated. For research use only. For in vitro diagnosis use only. 

Product Description

The Ostase® BAP EIA Assay is an in-vitro device indicated for the quantitative measurement of bone-specific alkaline phosphatase (BAP), an indicator of osteoblastic activity in human serum1,2.
This device is intended to be used as an aid in the management of postmenopausal osteoporosis and Paget’s disease.
Ostase® is a registered trademark of Hybritech Incorporated, a subsidiary of Beckman Coulter, Inc.

Unique Features


  • Fast turnaround time – results in approximately half the time of other manual assays. (1h 15 mins. total incubation with <30 mins. hands-on time)
  • Measures bone specific alkaline phosphatase (BAP) with low interference from other alkaline phosphatase isoforms
  • Excellent limit of detection (<1.0 μg/L)
  • Clinically relevant assay range – accommodates samples in a wide dynamic range (7-90 μg/L)
  • Excellent correlation with automated methods
  • Complementary – ideal companion product to Immunodiagnostic Systems Limited continually growing bone marker range
  • A complete assay panel supporting bone disease management

Scientific Description

Serum levels of BAP are believed to reflect the metabolic status of osteoblasts. An accurate assessment of bone metabolism is critical for determining the severity of metabolic bone disease and responses to therapy.
Measurement of serum levels of BAP has been shown to be useful in evaluating patients with Paget’s disease, osteomalacia, primary hyperparathyroidism, renal osteodystrophy, osteoporosis and metastases to bone.


Cavalier E et al., Inter-method variability in bone alkaline phosphatase measurement: Clinical impact on the management of dialysis patients. Clin Biochem. 2014 Sep;47(13-14):1227-30.
Raisz L et al., Comparison of the effects of oestrogen alone and oestrogen plus androgen on biochemical markers of bone formation and resorption in postmenopausal women. J Clin Endocrin Metab. 1996; 81:37-43.



  1. Long-term biochemical response after bisphosphonate therapy in Paget’s Alvarez 2004 Rheumatology 43:869
  2. Spondylarthropathies:therapy【328-331】2004 Rheum-atology 43:129
  3. Bone Turnover in Prolonged Critical IIIness:Effect of Vitamin D Van Den Berghe 2003 J.Clin. Endocrinol.Metab.88:4623
  4. Increased Bone Mineral Density in Patients with Chronic Hypoparathyroidism Chan 2003 J.Clin.Endocrinol.Metab.88:3155
  5. Alendronate Prevents Loss of Bone Density Associated with Discontinuation of…Ascott-Evans 2003 Archives of Internal Medicine 163:789
  6. Osteoporosis and Vitamin-D Deficiency Among Postmenopausal Women with Osteoa…Glowachi 2003 J.Bone Joint Surg.Am.85:2371

Address:Rm. 405-410, 4th Floor, Bldg. B4, No. 11, Kaiyuan Avenue, Science City, Guangzhou Hi-tech Industrial Zone, Huangpu District, Guangzhou, Guangdong, China
Zip code:510530    Tel: 020-32293178  / 020-32293176
Fax: 020-32293177    Website:
Sales Department:
Tel:020-32293178 020-32293176
mobile phone: 18927505895   or
Technical support department: